- Home
- REGN vs MRSH Comparison
REGN vs MRSH Comparison
Compare REGN & MRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | MRSH |
|---|---|---|
| Founded | 1988 | 1871 |
| Country | United States | United States |
| Employees | 15410 | 55700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3B | 95.4B |
| IPO Year | 1995 | 1994 |
Fundamental Metrics
Financial Performance| Metric | REGN | MRSH |
|---|---|---|
| Price | $927.73 | $200.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 28 | 23 |
| Target Price | ★ $869.07 | $205.38 |
| AVG Volume (30 Days) | 612.2K | ★ 2.0M |
| Earning Date | 10-30-2026 | 10-15-2026 |
| Dividend Yield | 0.46% | ★ 2.01% |
| EPS Growth | ★ 8.19 | 3.06 |
| EPS | ★ 37.37 | 6.68 |
| Revenue | $5,872,227,000.00 | ★ $26,981,000,000.00 |
| Revenue This Year | $22.71 | $6.52 |
| Revenue Next Year | $5.64 | $4.87 |
| P/E Ratio | $42.97 | ★ $29.42 |
| Revenue Growth | ★ 20.82 | 10.32 |
| 52 Week Low | $591.52 | $156.60 |
| 52 Week High | $859.34 | $200.33 |
Technical Indicators
Market Signals| Indicator | REGN | MRSH |
|---|---|---|
| Relative Strength Index (RSI) | 78.71 | 70.93 |
| Support Level | $736.27 | $167.20 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 24.48 | 4.19 |
| MACD | 11.15 | 1.40 |
| Stochastic Oscillator | 93.79 | 93.79 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About MRSH Marsh Common Stock
Marsh is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.